О. Е. Ваизова

ORCID: 0000-0003-4083-976X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neurological Disorders and Treatments
  • Neurological Disease Mechanisms and Treatments
  • Diabetes Treatment and Management
  • Pancreatic function and diabetes
  • Diet, Metabolism, and Disease
  • Neonatal Respiratory Health Research
  • Neuroscience and Neuropharmacology Research
  • Metabolism, Diabetes, and Cancer
  • Cardiac Ischemia and Reperfusion
  • Apelin-related biomedical research
  • Computational Drug Discovery Methods
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Drug-Induced Hepatotoxicity and Protection
  • Pulmonary Hypertension Research and Treatments
  • Biomarkers in Disease Mechanisms
  • Biochemical Acid Research Studies
  • Biochemical effects in animals
  • Medicinal Plants and Bioactive Compounds
  • Signaling Pathways in Disease
  • Diet and metabolism studies
  • Phagocytosis and Immune Regulation
  • Respiratory viral infections research
  • Diabetes and associated disorders
  • Cancer therapeutics and mechanisms
  • Metabolism and Genetic Disorders

Siberian State Medical University
1994-2025

Ministry of Health of the Russian Federation
2017-2024

Vladivostok State Medical University
2024

Tomsk National Research Medical Center
1995-2018

Research Institute of Pharmacology and Regenerative Medicine named ED Goldberg
2018

Russian Academy of Sciences
1994-2018

Institute of Pharmacology
1994-1995

Academy of Medical Sciences
1994-1995

Tomsk Cancer Research Institute
1995

Pharmacology Research Institute
1994

Introduction. Cancer is the leading cause of death worldwide. Naphthoquinones are a group natural organic compounds with wide range activity, including cardio-, hepato-, neuroprotective effects, as well antimicrobial, anti-inflammatory and antitumor activity. 1,4-naphthoquinone easily oxidized, reduced, may be attached nucleophiles. Well-developed methods chemical modification naphthoquinones make them attractive for development new types substances. It known about effect naphthoquinone –...

10.33380/2305-2066-2025-14-1-1852 article EN cc-by Drug development & registration 2025-02-14

In clinical practice, there are patients with a combination of metabolic syndrome (MS) and chronic obstructive pulmonary disease (COPD). The pathological mechanisms linking MS COPD largely unknown. It remains unclear whether the effect (possible obesity) has major impact on progression COPD. This complicates development effective approaches for treatment diagnosis Experiments were performed female C57BL/6 mice. Introduction monosodium glutamate extract cigarette smoke was modeled to simulate...

10.3390/ijms20051105 article EN International Journal of Molecular Sciences 2019-03-04

In clinical practice, the metabolic syndrome (MetS) is often associated with chronic obstructive pulmonary disease (COPD). Although gender differences in MetS are well documented, little known about sex-specific pathogenesis of COPD, especially when combined MetS. Consequently, it not clear whether same treatment regime has comparable efficacy men and women diagnosed COPD. present study, using sodium glutamate, lipopolysaccharide, cigarette smoke extract, we simulated lipid metabolism...

10.3390/ijms20215414 article EN International Journal of Molecular Sciences 2019-10-30

In clinical practice, the metabolic syndrome can lead to multiple complications, including diabetes. It remains unclear which component of (obesity, inflammation, hyperglycemia, or insulin resistance) has strongest inhibitory effect on stem cells involved in beta cell regeneration. This makes it challenging develop effective treatment options for complications such as our study, experiments were performed male C57BL/6 mice where disorders have been introduced experimentally by a combination...

10.3390/ijms21030991 article EN International Journal of Molecular Sciences 2020-02-03

Glucagon-like peptide-1 (GLP-1) is a hormone possessing extensive pharmacologic potential. Additionally, to its multiple metabolic effects, GLP-1 also exhibits cardiac and neuroprotective effects. Native not used as medicinal agent, however, now analogues structurally similar it having long-lasting effect have been developed in the treatment of type 2 diabetes mellitus (T2DM). The review focuses on these drugs discusses possible mechanisms this effect. Aim: To identify information about...

10.52667/2712-9179-2024-4-2-11 article EN Personalized Psychiatry and Neurology 2024-09-18

Objective: This study assessed the patterns and clinical significance of potential drug–drug interactions (pDDIs) in patients with diseases cardiovascular system. Methods: Electronic health records (EHRs), established 2018–2023, were selected using probability serial nested sampling method (n = 1030). Patients aged 27 to 95 years (65.0% men). Primary diagnosis COVID-19 was present 17 EHRs (1.7%). Medscape Drug Interaction Checker used characterize pDDIs. The Mann–Whitney U test chi-square...

10.3390/jcm13154289 article EN Journal of Clinical Medicine 2024-07-23

Aim. To consider the use of galectin-1 and galectin-3 inhibitors as potential pharmacological targets in antitumor antifibrotic therapy. The lecture includes analysis experimental research review articles presented PubMed database. A brief description structure galectins is given. Their generally accepted classification features carbohydrate recognition domain are presented. main part describes results on development carbohydrate-based (β-galactoside derivatives or analogues)...

10.20538/1682-0363-2024-3-155-162 article EN cc-by Bulletin of Siberian Medicine 2024-10-11

Introduction . The potential of a new compound in the ongoing drugs discovery process is initially explored using virtual instruments, where its activity predicted based on molecular structure. Aim This study aimed to evaluate pharmacokinetic parameters and possible toxicity isobornyl compounds tools. Material Methods Several free Internet resources were used assess absorption, distribution, metabolism, excretion (ADME), (T) 2,6-diisobornyl-4-methylphenol (1, Dibornol),...

10.29001/2073-8552-2020-35-4-79-86 article EN Siberian Journal of Clinical and Experimental Medicine 2020-12-25

This article presents the results of follow-up 150 patients in recovery period after ischemic stroke (the mean age – 58,7 years). According to randomization 76 additionally basic therapy received citicoline treatment and 74 consisted control group. In group neurological deficit was significantly less than Efficacy higher with one or two risk factors. There no benefit from additional three

10.18821/1560-9545-2014-19-1-44-48 article EN The Neurological Journal 2015-06-30
Coming Soon ...